Zevra Therapeutics Inc (ZVRA)
4.65
-0.26
(-5.30%)
USD |
NASDAQ |
Jun 14, 16:00
4.65
0.00 (0.00%)
After-Hours: 20:00
Zevra Therapeutics Free Cash Flow: -45.66M for March 31, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| March 31, 2024 | -45.66M |
| December 31, 2023 | -33.83M |
| September 30, 2023 | -22.10M |
| June 30, 2023 | -23.92M |
| March 31, 2023 | -19.32M |
| December 31, 2022 | -18.81M |
| September 30, 2022 | -15.18M |
| June 30, 2022 | -11.29M |
| March 31, 2022 | 9.354M |
| December 31, 2021 | 10.34M |
| September 30, 2021 | 10.12M |
| June 30, 2021 | 11.80M |
| March 31, 2021 | -2.525M |
| December 31, 2020 | -1.972M |
| September 30, 2020 | -3.99M |
| June 30, 2020 | -5.172M |
| March 31, 2020 | -14.71M |
| December 31, 2019 | -23.76M |
| September 30, 2019 | -35.67M |
| Date | Value |
|---|---|
| June 30, 2019 | -49.40M |
| March 31, 2019 | -51.21M |
| December 31, 2018 | -54.22M |
| September 30, 2018 | -46.15M |
| June 30, 2018 | -40.40M |
| March 31, 2018 | -37.76M |
| December 31, 2017 | -33.28M |
| September 30, 2017 | -35.79M |
| June 30, 2017 | -34.19M |
| March 31, 2017 | -36.10M |
| December 31, 2016 | -30.42M |
| September 30, 2016 | -27.41M |
| June 30, 2016 | -23.47M |
| March 31, 2016 | -20.31M |
| December 31, 2015 | -20.40M |
| September 30, 2015 | -20.95M |
| June 30, 2015 | -20.18M |
| March 31, 2015 | -17.85M |
| December 31, 2014 | -14.72M |
Free Cash Flow Range, Past 5 Years
-49.40M
Minimum
Jun 2019
11.80M
Maximum
Jun 2021
-14.28M
Average
-14.95M
Median
Free Cash Flow Benchmarks
| Dare Bioscience Inc | -30.19M |
| ENDRA Life Sciences Inc | -9.220M |
| OptiNose Inc | -32.43M |
| Kodiak Sciences Inc | -175.76M |
| INmune Bio Inc | -18.32M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -16.16M |
| Cash from Investing (Quarterly) | 14.79M |
| Cash from Financing (Quarterly) | 1.217M |
| Free Cash Flow Per Share (Quarterly) | -0.3869 |
| Free Cash Flow to Equity (Quarterly) | -16.40M |
| Free Cash Flow to Firm (Quarterly) | -16.16M |
| Free Cash Flow Yield | -25.85% |